Page 1 | Search Results | Blood Advances | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1 , GATA2 , and DDX41

Claire C. Homan, Michael W. Drazer, Kai Yu, David M. Lawrence, Jinghua Feng, Luis Arriola-Martinez, Matthew J. Pozsgai, Kelsey E. McNeely, Thuong Ha, Parvathy Venugopal, Peer Arts, Sarah L. King-Smith, Jesse Cheah, Mark Armstrong, Paul Wang, Csaba Bödör, Alan B. Cantor, Mario Cazzola, Erin Degelman, Courtney D. DiNardo, Nicolas Duployez, Remi Favier, Stefan Fröhling, Ana Rio-Machin, Jeffery M. Klco, Alwin Krämer, Mineo Kurokawa, Joanne Lee, Luca Malcovati, Neil V. Morgan, Georges Natsoulis, Carolyn Owen, Keyur P. Patel, Claude Preudhomme, Hana Raslova, Hugh Rienhoff, Tim Ripperger, Rachael Schulte, Kiran Tawana, Elvira Velloso, Benedict Yan, Erika Kim, Raman Sood, Amy P. Hsu, Steven M. Holland, Kerry Phillips, Nicola K. Poplawski, Milena Babic, Andrew H. Wei, Cecily Forsyth, Helen Mar Fan, Ian D. Lewis, Julian Cooney, Rachel Susman, Lucy C. Fox, Piers Blombery, Deepak Singhal, Devendra Hiwase, Belinda Phipson, Andreas W. Schreiber, Christopher N. Hahn, Hamish S. Scott, Paul Liu, Lucy A. Godley, Anna L. Brown

Blood Adv (2023) 7 (20): 6092–6107.

https://doi.org/10.1182/bloodadvances.2023010045

Published: 2023

Includes: Supplemental data

Journal Articles

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Blood Adv (2022) 6 (13): 4006–4014.

https://doi.org/10.1182/bloodadvances.2022007378

Published: 2022

Includes: Supplemental data

Journal Articles

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

Dai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, Constance Yuan, Hao-Wei Wang, Hong Zhou, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, Julie Feurtado, Lacey James-Echenique, Chin-Hsien Tai, Keyur P. Patel, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Alina Dulau-Florea, Robert J. Kreitman

Blood Adv (2021) 5 (23): 4807–4816.

https://doi.org/10.1182/bloodadvances.2021005039

Published: 2021

Journal Articles

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Blood Adv (2021) 5 (8): 2173–2183.

https://doi.org/10.1182/bloodadvances.2020004173

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, Jing Ning, Miguel J. Franquiz, Rashmi Kanagal-Shamanna, Keyur P. Patel, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Koichi Takahashi, Marina Konopleva, Naval Daver, Ghayas C. Issa, Michael Andreeff, Hagop Kantarjian, Tapan M. Kadia

Blood Adv (2020) 4 (22): 5681–5689.

https://doi.org/10.1182/bloodadvances.2020003120

Published: 2020

Includes: Supplemental data

Journal Articles

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Helen T. Chifotides, Lucia Masarova, Mansour Alfayez, Naval Daver, Yesid Alvarado, Elias Jabbour, Marina Konopleva, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo, Srdan Verstovsek

Blood Adv (2020) 4 (21): 5336–5342.

https://doi.org/10.1182/bloodadvances.2020001528

Published: 2020

Journal Articles

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Blood Adv (2020) 4 (8): 1670–1677.

https://doi.org/10.1182/bloodadvances.2019001156

Published: 2020

Includes: Supplemental data

Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Blood Adv (2020) 4 (7): 1311–1320.

https://doi.org/10.1182/bloodadvances.2019001267

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

Blood Adv (2020) 4 (6): 1038–1050.

https://doi.org/10.1182/bloodadvances.2019001396

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

NARROW

Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1 , GATA2 , and DDX41

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only